

**Worldwide Cancer Research
Limited by Guarantee**

**Directors' report and financial statements
for the year to 31 December 2021**

Company number SC152991

Charity number SC022918

Contents

	Page
Company information	1
Directors' report	2 - 7
Statement of Directors' responsibilities	8
Report of the auditors	9 - 12
Statement of financial activities (incorporating income and expenditure account)	13
Balance sheet	14
Cash flow statement	15
Notes to the financial statements	16 - 32

Company information

Directors	David MB Sole OBE Rosalind A Cuschieri BSc (Hons) Jane S Brydon Julia M Porter Sue E Hunter LLB (Hons), Dip LP, APFS CFP Prof Kevin J Hiom BSc PhD Prof Iain A McNeish MA, BM BCh, PhD, FRCP Beverley J Brookes BA (Hons) Prof Paul J Coffey BA, PhD Chris Clark MA (Hons)	(Committees: A, N chair, F chair)* (Committees: N) (Committees: R chair) (Committees: F chair) (Committees: A, R) (Committees: RS) (Committees: RS) (Committees: F) (Committees: RS) (Committees: A chair, R)
Chief executive	Dr Helen Rippon BSc (Hons) PhD	
Secretary	Adam Cobham MA(Hons) CA	
Registered office	1 st Floor, Canning Exchange 10 Canning Street Edinburgh EH3 8EG	
Auditors	Henderson Loggie LLP Chartered Accountants 11-15 Thistle Street Edinburgh EH2 1DF	
Bankers	The Royal Bank of Scotland plc South Street St Andrews Fife KY16 9QB	
Investment advisors	Brewin Dolphin Ltd Sixth Floor, Atria One 144 Morrison Street Edinburgh EH3 8BR	
Solicitors	Thorntons Law LLP Kinburn Castle St Andrews Fife KY16 9DR	
Charity number	SC022918	

* A: Member of Audit Committee F: Member of Fundraising Committee N: Member of Nominations Committee
R: Member of Remuneration Committee RS: Research Strategy Committee

Directors' report

General

The Directors have pleasure in presenting their annual report and the financial statements of the charity for the year ended 31 December 2021.

The financial statements have been prepared in accordance with the accounting policies set out in note 1 to the financial statements and comply with the Charities and Trustee Investment (Scotland) Act 2005, the Charities Accounts (Scotland) Regulations 2006 (as amended), the Companies Act 2006 and the Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their financial statements in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) issued during July 2014.

Objectives and activities

Worldwide Cancer Research's vision is to end cancer by starting new cancer cures worldwide. The charity stands for people with cancer, with its objectives focused on ending their suffering and enhancing their quality of life by promoting, funding and supporting new strands of scientific research that meet four key criteria:

- Starting new ideas
- Exciting and creative
- Scientific quality
- Transformative impact

It is by funding research of this nature, and promoting publication of its findings, that Worldwide Cancer Research seeks to accelerate progress in the understanding of cancer and finding new methods of prevention, diagnosis and treatment.

Today we fund around 20 to 25 early stage cancer research projects a year (typically £4m to £5m). The charity has plans for significant growth with the ambition to fund £20m of new research, or 100 new research projects, annually in 10 years' time. Achieving this level of research funding is underpinned by a fundraising strategy centred on major growth and diversification in fundraising income.

Historically, the key fundraising income streams were monthly direct debit giving and a rolling prize draw programme, creating sustainable cash flow into the charity. These supporters continue to be the lifeblood of the charity, but the Board recognised in 2019 that supporter numbers must be increased and fundraising activities diversified to ensure the long term stability of the charity. The principal impact of the pandemic on Worldwide Cancer Research was to delay plans for planned investment in 2020, and to some extent also in 2021, to increase awareness of its work, the number of its supporters and its income.

The 'Curestarter' fundraising strategy which is now being delivered focuses on modernisation and diversification through community building. The charity seeks to build a community of Curestarters by improving and modernising its individual programme via digital transformation and widening our philanthropic reach through trusts and major donors.

To facilitate this, we plan to invest in fundraising over the coming years to build our curestarter community. Alongside this we will fund research at a higher level, in which started in 2021, gradually stepping towards the £20m research funding target as we grow fundraising income.

The charity is able to adopt this strategy from a position of great financial strength. Over the last four years, the Board has had a deliberate strategy of building up reserves following a challenging financial period. In conjunction with almost two years of prudent stewardship during the pandemic this has resulted in the charity building significant reserves. Over the coming years, commencing in 2022, the charity will be able to both fund higher levels of research funding in the year, and also support a higher level of investment in fundraising to secure significantly greater levels of research funding in the medium term. We plan to increase research funding levels in sustainable steps providing stability and further assurance for the research community. Delivery of this strategy will gradually reduce the level of reserves held by the charity.

The funds raised by the charity are reduced by the cost of raising the funds and the governance costs of the charity. The Board aims to ensure costs are kept to a minimum, while ensuring proper controls,

Directors' report *(continued)*

Objectives and activities *(continued)*

procedures and governance are upheld. These efforts aim to maximise the net availability of funds for the support of high quality cancer research.

Worldwide Cancer Research's policy for grant making is to award grants only to projects which meet demanding criteria set by the charity's Research Strategy Committee. These criteria are then used by the Scientific Advisory Committee in its review of the grant applications and its awarding decisions. The Committee comprises 24 of Europe's leading researchers across a wide range of cancer-related fields.

The work of the Committee is further enhanced by a global peer review process involving over 1,500 scientists around the world, all of whom are specialists in their field. The procedures followed by the Committee and the peer reviewers are rigorous and make considerable time demands, all of which is provided on a voluntary basis.

While the Board may from time to time vary the grant making policy and determines the financial limit of funding, it does not interfere with the Committee's recommendations on project funding. The work of successful grant applicants is monitored through regular reporting and communication with the research team and their institution. Worldwide Cancer Research reserves the right to terminate grant funding in accordance with the contract with the grant holder. This would generally only be exercised if the terms of the grant award are not met.

Achievements and performance

During the period, the charity successfully delivered significant growth (11%) in fundraising income for the first time in recent years despite the challenging fundraising environment. In light of the COVID-19 pandemic we continued the focus from 2020 on stewardship and retention of existing supporters along with a strong focus on cost control. The charity also commenced new supporter acquisition both on the rolling prize draw programme and digital acquisition of new supporters and leads. A robust programme of test and learn provided positive signs in supporter acquisition, which underpins the strategic aim to establish a strong individual giving. Net income increased year on year reflecting income growth, most notably on legacies, supporter acquisition and strong cost management while not compromising on the good governance of the charity. The Directors are confident that further investment will result in growth in supporter numbers and income over the coming years.

Despite the challenging external environment, the Directors were pleased to open a grant round during the year. This entire process was successfully run digitally for the second year running, including holding the key Scientific Advisory Committee meeting online. This culminated in a decision to fund £4.9 million of new research in November 2021 comprising 26 new grants across 11 countries. This level of commitment is consistent with the Charity's objectives and is judged to be manageable within the Charity's overall financial position. This is a significant increase on the grants awarded in 2020 (£3.2 million) and it also represents the highest level of funding and number of new grants the charity has awarded for five years. This is an important step towards the charity's 10 year objective of funding £20 million of new research each year.

In addition, the charity entered into three new research funding partnerships to co-fund research that meets the charitable objectives of each partner. These partnerships, with FC-AECC, Cancer Australia and Pancreatic Cancer UK, allow the charity to leverage the work of the Scientific Advisory Committee to ensure more research is funded overall. These co-funding arrangements increased the total research funded from the £4.9m noted above to £5.2 million in total.

The ratio of spend between charitable activities and raised funds has increased significantly from 2020 to 2021 with spend on charitable activities increasing by £3 million (80%) while fundraising costs were broadly stable.

The Directors note that whilst the charity has come through the pandemic so far in a robust financial position, there are new risks on the horizon, including the international geopolitical situation and the significant cost of living challenges which have emerged in recent months.

Directors' report *(continued)*

Achievements and performance *(continued)*

The Directors report that Worldwide Cancer Research ended the period with a positive reserve position and having passed its reserve test, denoting a secure financial footing. As noted above this means that, commencing in 2022, the charity will be able to both fund higher levels of research funding and also support a higher level of investment in fundraising to secure greater, sustainable, levels of research funding in the medium term. This will gradually reduce the level of reserves held by the charity.

The Directors also highlight the significant research funding that continued during the period. At December 2021, the charity had 75 active projects across 16 different countries.

The Directors wish to thank all members of staff for their continuing commitment in a wide range of roles, particularly in this year where the charity has again been through significant challenges resulting from the pandemic including an extended period of working from home across the organisation. Without the efforts and enthusiasm of the staff team Worldwide Cancer Research's work would be impossible, and it is thanks to all of them that the charity remains an inspiring place to work. Heartfelt thanks are above all given to our thousands of curestarter supporters. Every contribution is valued, no matter how large or small.

Financial review

In both 2020 and 2021, the financial impact of the COVID-19 pandemic on the charity has been relatively limited compared to that seen elsewhere in the sector.

- Retention of existing supporters has been strong despite the continued impact of the pandemic. This reflects the additional focus of the charity on this area through 2020 and 2021.
- New supporter acquisition activity recommenced in 2021 with notable success on both the rolling prize draw programme and new cash donors.
- The value of the charity's investment portfolio has been impacted by market volatility during the year but closed the year 7% (£1.1m) higher than at the end of 2020.
- Payments to grant holders continued to fluctuate as research institutions were more broadly impacted by the pandemic. The charity has worked closely with each of the currently funded research teams to support continued successful delivery of projects.

The charity reported increased fundraising income for the period, the first year on year income growth since 2014. This combined with strict control over the costs of running the charity ensured an improved financial position by the period end, along with a significant increase in the level of grant funding awarded. Income for the period was £10.8 million (2020 - £9.7 million) and expenditure on charitable activities was £6.7 million (2020 - £3.7 million).

Fundraising costs for the period were £3.0 million (2020 - £3.1 million) as the charity made every effort to control its costs alongside investment in new supporter acquisition. The net positive return on investments totalled £0.8 million (2020 - £0.7 million). The resulting Income and Expenditure account shows net income of £1.8 million (2020 - £3.6 million).

The charity's accounting policy requires that all liabilities of whatever duration be accounted for each year. The continued deployment of a prudent financial strategy has improved the balance sheet to a net asset position as at 31 December 2021 of £11.4 million (2020 - £9.6 million). This includes £48,586 (2020 - £79,883) tied up in fixed assets, leaving £11.36 million (2020 - £9.55 million) of free reserves. The Directors are confident that existing cash of £6.3 million and investments of £15.8 million (2020 - £4.4 million and £14.8 million) are more than adequate to cover all of the charity's liabilities.

Under the Articles of Association, the Directors have wide powers to invest any funds which are not immediately required for the Company's activities. The charity has adopted an element of negative screening most notably in ensuring no investment in tobacco companies. A review of investment managers and investment policy was completed in 2021 with the appointment of new investment managers and a full review of the charity's investment policy.

Directors' report *(continued)*

Reserves policy and going concern

In the context of the COVID-19 pandemic, the directors adopted a conservative and cautious approach to reserves. Reductions in the grant round and operational expenditure in 2020 and continued prudence in 2021 resulted in a strong reserves position at the end of the year. In addition to net assets on the Balance Sheet, the Directors utilise a reserve test to ensure that Worldwide Cancer Research maintains a stable and liquid financial position so that it can meet all of its commitments when they are due. The reserve test requires that liquid assets (cash and investments) must be greater than 24 months of projected cash outflows for grant commitments plus 6 months of projected operating expenses. At the period end, the reserve test was passed by a margin of £9.3 million. The Directors therefore believe it is appropriate to present these financial statements on a going concern basis. As noted above the Directors plan to gradually reduce the level of reserves through higher levels of research funding, and further investment in supporter acquisition over the medium term.

Plans for future periods

Worldwide Cancer Research's key goals are to open for applications for grant funding in the new fiscal year, to ensure the charity retains its financial stability and to continue with plans to invest in fundraising initiatives to significantly increase the number of supporters of the charity. As noted above, over the longer term, the charity has plans for significant growth with the ambition to fund £20m of new research, or 100 new research projects, annually in 10 years' time. Achieving this level of research funding is underpinned by a fundraising strategy centred on major growth and diversification in fundraising income.

Key investment areas for 2022 include a face to face acquisition campaign to attract new regular giving supporters and continued acquisition of rolling prize drawer players, cash donors. Investment will also be made on our philanthropic activity, investing in establishing a high value giving club and events programme, whilst improving our Legacy pipeline, a key area of growth for the charity's ambitions.

The charity intends to continue to increase spend on charitable activities alongside the investment in growing fundraising income. The Directors will continually assess fundraising and financial performance in order to ensure these goals can be met, recognising that significant growth may take several years.

Structure, governance and management

Worldwide Cancer Research is a private company limited by guarantee, governed by a Memorandum and Articles of Association and is a registered charity (Charity Number SC022918). The liability of the members is limited to £1. Permission has been granted by the Secretary of State for Business, Energy and Industrial Strategy for the word "Limited" to be omitted.

The Directors are the Trustees of Worldwide Cancer Research. Strong governance structures are in place. The Board of Directors meets no fewer than four times per year. There are five committees of Directors: a Nominations Committee to oversee the recruitment of new Directors, an Audit Committee to supervise the charity's finances; a Fundraising Committee to oversee key elements of the charity's fundraising strategy, a Remuneration Committee to oversee the setting of remuneration policies, and a Research Strategy Committee to oversee the charity's research funding.

The Board of Directors is responsible for the overall direction and control of the charity's activities. The Directors are independent and come from a wide range of backgrounds; any potential conflicts of interest are declared (Note 17 to the financial statements). Apart from approved expenses, no Director receives remuneration from Worldwide Cancer Research.

The Board of Directors seeks to ensure that its members possess the diverse skills and experience required for the good governance of the charity. Whenever a vacancy occurs, or is anticipated, a replacement candidate matching the Board's skill needs is sought by the Nominations Committee.

The procedure for subsequent appointment to the Board is set out in Worldwide Cancer Research's Articles of Association. No external body has any right of appointment to the Board.

Directors' report *(continued)*

Structure, governance and management *(continued)*

It is the policy of Worldwide Cancer Research that any new Director thoroughly understands the aims and objectives of the charity and its methods of operation. Implementation of this policy starts before appointment to the Board via informal discussions with existing Directors and the Chief Executive and continues with on-going briefings and explanations. A package of induction materials is provided to new Directors on their appointment.

Induction and training ensure that Directors understand their statutory duties and responsibilities in general and, more specifically, with reference to Worldwide Cancer Research. Most of the current Directors have many years of experience of working in the charity sector but external training is brought to the attention of Directors and, where a need is identified, is supported by the charity.

Worldwide Cancer Research currently employs less than 50 staff. Fundraising and marketing activities by the charity's staff raise significant amounts of money, but a major part of fundraising is contracted out to third party agencies. Contract negotiations and ongoing monitoring ensure that the activities of third-party agencies are cost-effective and ethical. Training by charity staff, including the Chief Executive, emphasises a code of conduct to govern the relationship between fundraiser and potential donor. Any queries or complaints are dealt with promptly, by telephone or in writing as appropriate.

The Board of Directors discharges its responsibilities by well-informed and open discussion at meetings of the Board, and Board sub committees, which are always preceded by circulation of an agenda and relevant information papers. The aim of these meetings is to ensure that the Chief Executive and Senior Management team have a clear strategic and financial framework within which to exercise their delegated authority. Whilst the Board reserves to itself the authorisation of major capital expenditure, it delegates to the Chief Executive wide authority to act within plans and budgets approved by the Board.

The Chief Executive thus has powers sufficient for the day to day management of the organisation; she may, at her discretion, delegate powers to other members of staff. The Chief Executive is also required to identify and develop new policies and strategic ventures for consideration by the Board.

Board Performance

A review of Board performance is conducted annually. No significant findings were noted from the current year's review. Additional training was provided to Trustees reflecting feedback from the prior year performance review.

Directors

The Directors of the charitable company who held office at the date of this report are shown on page 1.

Related parties

Professor Paul J Coffey has links with the University Medical Center, Utrecht, Professor Kevin J Hiom has links with the University of Dundee, and Professor Iain A McNeish has links with Imperial College London. Grants may be awarded to these Universities.

Risk management

The Directors assess the major risks to which Worldwide Cancer Research is exposed at every Board meeting in order to satisfy themselves that systems are in place to mitigate the exposure to those risks.

The Directors have a risk management strategy which comprises:

- An annual review of the principal risks and uncertainties that the charity faces;
- The establishment of policies, systems and procedures to mitigate those risks identified in the annual review; and
- The implementation of procedures designed to minimise or manage any potential impact on the charity should those risks materialise.

Directors' report *(continued)*

Structure, governance and management *(continued)*

This work has identified that, despite a stable reserve position, medium term financial sustainability is the major risk facing the charity due to reducing levels of income. To address this, the charity continues to invest in a diversified fundraising strategy and to prudently manage expenditure in order to protect the financial stability of the charity.

The charity is also faced by the risk of future poor performance in its investment portfolio. The Directors consider variability of investment returns to constitute the charity's financial risk. This risk is mitigated by the allocation of a significant portion of the portfolio to less volatile assets and is further mitigated by retaining expert investment managers, together with a diversified investment portfolio strategy.

The management of the charity and the Board are closely monitoring the current position in respect of COVID-19 including the recent impact on investment valuations across the market.

Unrestricted funds and dividends

The Constitution of the charitable company specifically prohibits the distribution of income by way of dividend, bonus or otherwise to the members of the charitable company.

Key management

The Directors consider key management to be the Board of Directors, in terms of setting strategy and policy and assessing risk, and the Chief Executive Officer in terms of directing and operating the charity on a day to day basis.

The remuneration of the Chief Executive Officer is reviewed annually and may be increased in certain circumstances, including benchmarking against other charitable companies of a similar size and nature. The Chief Executive received no pay increase during the year. No Director received any remuneration from the company, other than approved expenses. Details of remuneration and expenses are disclosed in note 7 to the financial statements.

Status of company and liability of members


On the winding up of the charitable company every member has undertaken to contribute to the assets of the charitable company for the payment of the debts and liabilities and of the cost of winding up of the charitable company, such amount as may be required not exceeding one pound. If the winding up occurs within one year of a member ceasing to be a member then the above applies for debts and liabilities of the charitable company contracted for before he ceased to be a member.

Auditors

So far as each Director is aware there is no relevant audit information of which the auditor is unaware. Each Director has taken all the steps that they ought to have taken as a Director to make themselves aware of all relevant audit information and to establish that the auditor is aware of it.

The auditors have expressed their willingness to continue in office and will be deemed to be reappointed under Section 487 of the Companies Act 2006.

The financial statements and the report on pages 2 to 7 were approved by order of the Board of Directors:


David Sole - 2022-04-22, 09:54:52 UTC

David MB Sole
Chair

Statement of Directors' responsibilities

The Directors (who are also the Trustees of Worldwide Cancer Research for the purposes of charity law) are responsible for preparing the Directors' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the Directors to prepare financial statements for each financial period which give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that period. In preparing these financial statements, the Directors are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in business.

The Directors are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 and the Charities Financial statements (Scotland) Regulations 2006 (as amended). They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The Directors are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

Independent Auditor's Report to the Directors and Members of Worldwide Cancer Research

Opinion

We have audited the financial statements of Worldwide Cancer Research (the 'charitable company') for the year ended 31 December 2021 which comprise the statement of financial activities (including income and expenditure account), balance sheet, cash flow statement and notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including FRS 102 *The Financial Reporting Standard applicable in the UK and Republic of Ireland* (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the charitable company's affairs as at 31 December 2021 and of its income and expenditure for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 and Regulation 8 of the Charities Accounts (Scotland) Regulations 2006 (as amended)

Basis of opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the Directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charitable company's ability to continue as a going concern for a period of at least 12 months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the Directors with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the Directors' report, other than the financial statements and our auditor's report thereon. The Directors are responsible for the other information. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

Independent Auditor's Report to the Directors and Members of Worldwide Cancer Research *(continued)*

Other information *(continued)*

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of our audit:

- the information given in the Directors' Report for the financial period for which the financial statements are prepared is consistent with the financial statements; and
- the Directors' Report has been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the charitable company and its environment obtained in the course of the audit, we have not identified material misstatements in the Directors' Report.

We have nothing to report in respect of the following matters where the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 and the Charities Accounts Regulations 2006 (as amended) requires us to report to you if, in our opinion:

- adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of Directors' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit.

Responsibilities of directors

As explained more fully in the Directors' Responsibilities Statement, the Directors (who are also the Trustees of the charitable company for the purposes of charity law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the Directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Directors are responsible for assessing the charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Directors either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

Independent Auditor's Report to the Directors and Members of Worldwide Cancer Research *(continued)*

Auditor's responsibilities for the audit of the financial statements

We have been appointed as auditor under section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005 and under the Companies Act 2006 and report in accordance with the Acts and relevant regulations made or having effect thereunder.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The specific procedures for this engagement and the extent to which these are capable of detecting irregularities, including fraud is detailed below:

- Enquiring with management about any known or suspected instances of non-compliance with laws and regulations, including GDPR and employment law, and fraud;
- Review of correspondence with regulators including OSCR, the Gambling Commission and Health & Safety Executive;
- Review of legal fee expenditure and board minutes;
- Challenging assumptions and judgements made by management in their significant accounting estimates, and
- Auditing the risk of management override of controls, including through testing journal entries and other adjustments for appropriateness

Because of the field in which the client operates, we identified the following areas as those most likely to have a material impact on the financial statements: Health and Safety; employment law (including the Working Time Directive); gambling regulations; and compliance with the UK Companies Act, Charities and Trustee Investment (Scotland) Act 2005 and the Charities Accounts Regulations 2006.

Owing to the inherent limitations of an audit, there is an unavoidable risk that some material misstatements in the financial statements may not be detected, even though the audit is properly planned and performed in accordance with the ISAs (UK). For instance, the further removed non-compliance is from the events and transactions reflected in the financial statements, the less likely the auditor is to become aware of it or to recognize the non-compliance.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at <https://www.frc.org.uk/auditorsresponsibilities>. This description forms part of our auditor's report.

Independent Auditor's Report to the Directors and Members of Worldwide Cancer Research *(continued)*

Use of this report

This report is made solely to the Members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006, and to the charitable company's Directors, as a body, in accordance with Section 44 (1)(c) of the Charities and Trustee Investment (Scotland) Act 2005 and Regulation 10 of the Charities Accounts (Scotland) Regulations 2006 (as amended). Our audit work has been undertaken so that we might state to the Members and the charitable company's Directors those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company, its Members as a body and its Directors as a body, for our audit work, for this reporter for the opinions we have formed.


James Davidson - 2022-04-23, 10:52:21 UTC

James Davidson (Senior Statutory Auditor)

For and on behalf of Henderson Loggie LLP, Statutory Auditor
11-15 Thistle Street
Edinburgh
EH2 1DF

Statement of financial activities (incorporating income and expenditure account)


for the year ended 31 December 2021

2021	Note	Unrestricted funds £	Restricted funds £	2021 Total funds £	2020 Total funds £
Income:					
Donations and legacies	3	10,253,079	52,465	10,305,544	9,283,683
Other trading activities		141,984	-	141,984	82,837
Investment income		371,121	-	371,121	371,049
Total income		10,766,184	52,465	10,818,649	9,737,569
Expenditure:					
Raising funds		3,036,380	-	3,036,380	3,073,998
Charitable activities		6,683,386	52,465	6,735,851	3,735,720
Total expenditure	6	9,719,766	52,465	9,772,231	6,809,718
Net income before gains and losses on investments		1,046,418	-	1,046,418	2,927,851
Net gains on investments	9	761,001	-	761,001	653,591
Net income for the year		1,807,419	-	1,807,419	3,581,442
Transfer between funds		-	-	-	-
Net movement in funds		1,807,419	-	1,807,419	3,581,442
Reconciliation:					
Total funds brought forward		9,629,866	-	9,629,866	6,048,424
Total funds carried forward	12	11,437,285	-	11,437,285	9,629,866

Balance sheet
as at 31 December 2021

	Note	2021 £	2020 £
Fixed assets			
Tangible assets	8	48,586	79,883
Investments	9	15,825,908	14,756,307
		<hr/>	<hr/>
		15,874,494	14,836,190
		<hr/>	<hr/>
Current assets			
Debtors	10	2,099,768	1,353,933
Short term bank deposits		5,839,227	4,319,038
Cash at bank and in hand		477,162	128,017
		<hr/>	<hr/>
		8,416,157	5,800,988
		<hr/>	<hr/>
Creditors			
Amounts falling due within one year	11	(4,933,056)	(4,047,880)
		<hr/>	<hr/>
Net current assets/ (liabilities)		3,483,101	1,753,108
		<hr/>	<hr/>
Total assets less current liabilities		19,357,595	16,589,298
		<hr/>	<hr/>
Creditors			
Amounts falling due after more than one year	11	(7,920,310)	(6,959,432)
		<hr/>	<hr/>
Net assets		11,437,285	9,629,866
		<hr/> <hr/>	<hr/> <hr/>
Accumulated funds			
Unrestricted	12, 13, 14	11,437,285	9,522,350
Designated	12, 13, 14	-	107,516
		<hr/>	<hr/>
		11,437,285	9,629,866
		<hr/>	<hr/>
Restricted	12, 13, 14	-	-
		<hr/>	<hr/>
Total funds		11,437,285	9,629,866
		<hr/> <hr/>	<hr/> <hr/>

These financial statements were approved by the Board of Directors and were signed on its behalf by:


David Sole - 2022-04-22, 09:54:52 UTC

David MB Sole
Chair

Cash flow statement
for the year ended 31 December 2020

	Note	2021 £	2020 £
Net cash used in operating activities	15	1,806,813	2,274,392
Cash flows from investing activities			
Interest received		502	3,522
Investment income		370,619	367,527
Payments to acquire fixed asset investments		(14,310,003)	(2,592,608)
Receipts from sale of fixed asset investments		14,347,878	650,215
Net cash flows from investing activities		408,996	(1,571,344)
Net increase in cash and cash equivalents		2,215,809	703,048
Cash and cash equivalents at the beginning of the year		4,447,055	3,744,007
Cash and cash equivalents at end of the year		6,662,864	4,447,055
Components of cash and cash equivalents			
Cash at bank and in hand		477,162	128,017
Short term bank deposits		5,839,227	4,183,901
Cash held as part of investment portfolio		346,475	135,137
		6,662,864	4,447,055

Notes to the financial statements

1 Accounting policies

Charity information

Worldwide Cancer Research is a charitable private company registered in Scotland. The principal address is First Floor, Canning Exchange, 10 Canning Street, Edinburgh EH3 8EG.

Status of company and liability of members

Worldwide Cancer Research is a company limited by guarantee and does not have a share capital. Each member has undertaken to contribute an amount not exceeding one pound towards any deficit arising in the event of the charitable company being wound up.

Basis of accounting

The financial statements are prepared under the historical cost convention and include the results of the operations of the charitable company as indicated in the Directors' report. The financial statements incorporate the requirements of the Statement of Recommended Practice applicable to charities preparing their financial statements in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102), the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 and Regulation 8 of the Charities Accounts (Scotland) Regulations 2006 (as amended).

These financial statements are prepared in sterling, which is the functional currency of the charitable company. Monetary amounts in these financial statements are rounded to the nearest £.

Worldwide Cancer Research meets the definition of a public benefit entity under FRS 102.

The following is a summary of the significant accounting policies adopted by the charitable company in the preparation of the financial statements.

Going concern

At the time of approving the financial statements and having considered the impact of the COVID-19 pandemic, the Directors have a reasonable expectation that the charitable company has adequate resources to continue in operational existence for the foreseeable future.

Income

Other trading activities income is derived from fundraising events and is recognised in the period in which the charitable company is entitled to the income, it is probable that the income will be received, and the amount can be measured reliably.

Legacies are included when the charitable company is advised by the personal representative of an estate that payment will be made, property transferred, or there is entitlement, probable and reliably measured. The amount involved can be quantified. Where legacies have been notified to the charity, or the charity is aware of the granting of confirmation or probate and the criteria for income recognition have not been met, then the legacy is treated as a contingent asset and disclosed if material.

Dividends are recognised once the dividend has been declared and notification has been received of the dividend due. This is upon notification by our investment advisor of the dividend yield of the investment portfolio.

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the charitable company; this is normally upon notification of the interest paid or payable by the bank

Notes to the financial statements *(continued)*

1 Accounting policies *(continued)*

Expenditure and irrecoverable VAT

All expenditure is included on an accruals basis and is recognised when there is a legal obligation or constructive obligation to pay for expenditure, it is probable settlement will be required and can be measured reliably. Irrecoverable VAT is charged against the category of resources expended for which it was incurred as follows:

- Raising funds include expenditure associated with investment management and fundraising costs.
- Charitable activities include expenditure associated with grant making and support costs allocated on a basis consistent with the use of resources.

Expenditure in connection with donor recruitment is written off as incurred. Amounts paid in advance for other fundraising are carried forward and written off in the period in which the funds are raised.

Certain expenditure is directly attributable to specific activities and has been included in those cost categories. Certain other costs (Marketing and Fundraising Costs, Staff and Other costs), which are attributable to more than one activity, are apportioned across cost categories on the basis of an estimate of time spent on these activities within the charitable company's whole operations follows:

	M&F	Staff	Other
Raising funds – Fundraising and events costs	77%	55%	30%
Charitable activities – grants and education	23%	45%	70%

Research grants for most projects and programmes are awarded on a multi-year basis, with an ongoing review process. Grants are recorded as creditors for the full award based on the date of the Scientific Advisory Committee decision as this creates a constructive obligation for the full grant period as the liability is probable.

Depreciation

The cost or valuation of fixed tangible assets is depreciated to their estimated residual value over their estimated useful economic lives as follows:

Office equipment	-	20% straight line
Computer equipment	-	33 ¹ / ₃ % straight line

The charitable company does not capitalise any expenditure on individual items, or groups of items, of less than £5,000.

Retirement benefits

The charitable company operates an auto-enrolment defined contribution pension scheme for eligible employees who have not opted out. Employees who have opted out continue to receive pension contributions to their personal pension schemes. The charge in the financial statements represents amounts payable to employees' personal pensions and the company pension scheme for the year.

Leases

Rentals payable under operating leases, including any lease incentives received, are charged to income on a straight line basis over the term of the relevant lease except where another more systematic basis is more representative of the time pattern in which economic benefits from the lease asset are consumed.

Government grants

Government grants are recognised at the fair value of the asset received or receivable when there is reasonable assurance that the grant conditions will be met and the grants will be received. A grant that specifies performance conditions is recognised in income when the performance conditions are met. Where a grant does not specify performance conditions it is recognised in income when the proceeds are received or receivable. A grant received before the recognition criteria are satisfied is recognised as a liability.

Notes to the financial statements *(continued)*

1 Accounting policies *(continued)*

Foreign currency translation

Monetary assets and liabilities denominated in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are recorded at the rate ruling at the date of the transaction. All differences are taken to the income and expenditure account.

Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

Financial instruments

The company has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the charitable company's Balance Sheet when the company becomes party to the contractual provisions of the instrument.

The charitable company only has financial assets and financial liabilities of a kind that qualifies as basic financial instruments. Basic financial instruments are initially recognised as transaction value and subsequently measured at their settlement value.

Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense.

The cost of any unused holiday entitlement is recognised in the period in which the employee's services are received.

Termination benefits are recognised immediately as an expense when the charitable company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

Investments

Investments are included at fair value. Realised gains and losses, representing the difference between sale proceeds and cost or fair value are dealt with in the Statement of Financial Activities. Unrealised gains and losses, representing the movement in the fair value of investments over the financial year, or from their date of purchase if acquired during the financial year, are shown in note 9 and within the Statement of Financial Activities.

Unlisted investments are initially measured at cost and subsequently measured at cost less any accumulated impairment losses. The investments are assessed for impairment at each reporting date and any impairment losses or reversals of impairment losses are recognised immediately in income and expenditure.

Notes to the financial statements *(continued)*

1 Accounting policies *(continued)*

Research grants

Research grants are awarded at the discretion of the Directors normally for periods of one, two or three years. Research grants that are awarded and payable are disclosed as creditors.

Funds

All income and expenditure is dealt with through the Statement of Financial Activities. Funds are classified as either restricted funds or unrestricted funds, defined as follows:

Restricted funds are funds subject to specific trusts, which may be declared by the donor or with their authority (eg by the restrictive wording of an appeal).

Unrestricted funds are expendable at the discretion of the Directors in furtherance of the objects of the charitable company.

Designated funds are unrestricted funds earmarked by the Directors for identifiable future expenditure. Transfers are made from designated funds to restricted funds to cover additional expenditure incurred on grants funded by those restricted funds.

2 Judgements and key sources of estimation uncertainty

In the application of the charitable company's accounting policies, the Directors are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

Critical judgements

The following judgements (apart from those involving estimates) have had the most significant effect on amounts recognised in the financial statements.

Grant awards

Research grants for most projects and programmes are awarded on a multi-year basis, with an ongoing review process. Grants are recorded as creditors for the full award as at the date of the Scientific Advisory Committee decision, since this creates a constructive obligation for the full grant period as the liability is probable

Legacies

Legacies are included in income when the charitable company is advised by the personal representative of an estate that payment will be made, property transferred, or there is entitlement. The amount involved must be reliably quantifiable and receipt must be probable. Legacies advised that meet these criteria will be accounted for as a receivable in current assets until such time as distributions are received from the estate.

Notes to the financial statements *(continued)*

3 Donations and legacies

	2021 £	2020 £
Donations from direct mail fundraising	2,668,034	2,461,694
Regular giving	4,748,452	4,600,021
Other fundraising	353,010	464,611
CJRS grants	2,251	37,577
	7,771,747	7,563,903
Legacies	2,533,797	1,719,780
	10,305,544	9,283,683

In 2020, £249,837 of donations and legacies were restricted.

The charity is aware of 12 (2020: Nil) estates where the charity has been named as a beneficiary, but it has not been possible to measure reliably the amount due to be paid. The criteria for income recognition have not been met in these cases and these legacies have therefore not been accrued into these financial statements.

4 Net expenditure

	2021 £	2020 £
This is stated after charging/(crediting):		
Auditor's remuneration		
- audit services	14,490	13,680
- non-audit services	942	-
Depreciation	31,298	31,297
Operating lease rentals	97,249	75,259
	143,979	120,236

Notes to the financial statements *(continued)*

5	Grants payable	2021 £	2020 £
	Reconciliation of grants payable		
	Commitments accrued at 31 December 2020	10,825,640	10,879,733
		<hr/>	<hr/>
	Commitments made in the year	5,108,035	3,179,840
	Grants cancelled or recovered	(260,549)	(310,980)
		<hr/>	<hr/>
	Grants payable for the year (note 6)	4,847,486	2,868,860
	Grants paid during the year	(3,082,813)	(2,922,953)
		<hr/>	<hr/>
	Commitments accrued at 31 December 2021	12,590,313	10,825,640
		<hr/> <hr/>	<hr/> <hr/>
	Commitments accrued at 31 December 2021 are payable as follows:		
		2021 £	2020 £
	Within one year (note 11)	4,670,003	3,866,208
	After more than one year (note 11)	7,920,310	6,959,432
		<hr/>	<hr/>
		12,590,313	10,825,640
		<hr/> <hr/>	<hr/> <hr/>
	Grants are payable as follows:		
	Within 1 year	4,670,003	3,866,208
	Between 1 - 2 years	4,255,778	3,917,235
	Between 2 -5 years	3,664,532	3,042,197
		<hr/>	<hr/>
		12,590,313	10,825,640
		<hr/> <hr/>	<hr/> <hr/>

Grants are applied as creditors based on the award letter date as this creates a constructive obligation.

Research grants into the causes, prevention, treatment and cure of cancer and associated conditions are paid quarterly in arrears, on application by the grant holder.

All research grants are payable to institutions. Details of grants awarded in the current year can be found in Note 19 of the financial statements.

Notes to the financial statements (continued)

6 Total expenditure including allocation of support costs

	Fundraising costs		Grants		Education		2021 Total £
	Unrestricted £	Restricted £	Unrestricted £	Restricted £	Unrestricted £	Restricted £	
2021							
Grants (note 5)	-	-	4,795,021	52,465	-	-	4,847,486
Mailing Costs	179,263	-	-	-	53,546	-	232,809
Donor Recruitment	1,054,700	-	-	-	315,040	-	1,369,740
Office Costs	633,108	-	153,913	-	197,785	-	984,806
Bank Charges	8,892	-	31,121	-	4,446	-	44,459
Staff Costs (note 7)	981,943	-	664,478	-	115,879	-	1,762,570
Professional fees	5,941	-	20,795	-	2,971	-	29,707
Investment manager fees	1,896	-	6,636	-	948	-	9,480
Depreciation	6,260	-	21,909	-	3,130	-	31,299
Events costs	28,276	-	-	-	-	-	28,276
IT costs	53,132	-	185,963	-	26,566	-	265,661
Governance costs	82,969	-	82,969	-	-	-	165,938
	3,036,380	-	5,963,075	52,465	720,311	-	9,772,231
2020	3,073,998	-	3,311,586	-	424,134	-	6,809,718

The basis of cost allocation has been refined for 2021 to better reflect the split of expenditure between Fundraising and Charitable activities. Specifically for those costs which are attributable to more than one activity - including Marketing and Fundraising costs and Staff costs – the proportion of costs relating to each activity has been revised using estimates of where staff time is spent and the nature of the outputs of the activity.

Notes to the financial statements *(continued)*

6 Total expenditure including allocation of support costs (continued)

Governance costs	2021	2020
	£	£
Staff costs	135,198	140,464
Audit & Accountancy fees	18,013	18,125
Legal fees	12,727	14,609
	165,938	173,198

7 Staff costs and remuneration of key management personnel

	2021	2020
	£	£
Wages and salaries	1,573,737	1,479,408
Social security costs	162,904	152,102
Pension costs	161,127	147,116
	1,897,768	1,778,626

The average number of employees was:

2021	2020
44	42

The numbers of employees receiving emoluments, including pension contributions, of greater than £60,000 ranged as follows:

	2021	2020
£100,000 - £110,000	1	1
£ 80,000 - £ 90,000	-	-
£ 70,000 - £ 80,000	3	3
£ 60,000 - £ 70,000	1	-

Included in staff costs are redundancy payments of £18,360 (2020: £3,502). None of the Directors received any emoluments in respect of services provided during this or the preceding financial year. No Directors travel expenses were reimbursed during the year (2020: £202 reimbursed to 1 director).

Notes to the financial statements *(continued)*

7 Staff costs and remuneration of key management personnel *(continued)*

The remuneration of key management personnel is as follows:

	2021 £	2020 £
Salary *	102,000	103,159
Employers' National Insurance	12,857	13,029
Pension	10,200	9,750
	125,057	125,938
Aggregate compensation	125,057	125,938

* When applicable, includes a taxable travel allowance of up to £27,000 to cover the costs of ordinary commuting between the charitable company's main office in Scotland and her place of work in London

8 Tangible fixed assets

	Office furnishings and equipment £	Computer equipment £	Total £
2021			
Cost or valuation			
At 31 December 2020 & 31 December 2021	117,868	63,575	181,443
Depreciation			
At 31 December 2020	47,018	54,542	101,560
Charge for year	22,317	8,980	31,297
At 31 December 2021	69,335	63,522	132,857
Net book value			
At 31 December 2021	48,533	53	48,586
	70,849	9,033	79,883
At 31 December 2020	70,849	9,033	79,883

Notes to the financial statements (continued)

9 Investments

	2021	2020
	£	£
Listed investments	15,825,906	14,756,305
Unlisted investments	2	2
	<hr/>	<hr/>
	15,825,908	14,756,307
	<hr/> <hr/>	<hr/> <hr/>
		£
Historical cost at 31 December 2020		12,613,985
Unrealised profit		2,142,322
		<hr/>
Fair value at 31 December 2020		14,756,307
Movements during year:		
Purchases		14,310,003
Disposals		(14,347,878)
Realised gain on disposals		155,068
Increase in unrealised appreciation		605,933
Cash held as part of portfolio		346,475
Fair value at 31 December 2021		15,825,908
		<hr/> <hr/>
Historical cost at 31 December 2021		15,056,646
		<hr/> <hr/>
Net (losses)/gains on investments:	2021	2020
Realised gains on sales of investments	155,068	16,394
Increase/(Decrease) in unrealised appreciation of investments	605,933	637,197
	<hr/>	<hr/>
	761,001	653,591
	<hr/> <hr/>	<hr/> <hr/>

All listed investments are listed on a recognised Stock Exchange.

Cash balance of £346,475 (2020 - £135,137) is held within the charitable company's investment portfolio. In the prior year, this was shown within cash and bank balances.

Notes to the financial statements *(continued)*

9 Investments *(continued)*

Investment risks

FRS 102 requires the disclosure of information in relation to certain investment risks. These risks are set out by FRS 102 as follows:

Credit risk: this is the risk that one party to a financial instrument will cause a financial loss for the other party by failing to discharge an obligation.

Market risk: this comprises currency risk, interest rate risk and other price risk.

- **Currency risk:** this is the risk that the fair value or future cash flows of a financial asset will fluctuate because of changes in foreign exchange rates.
- **Interest rate risk:** this is the risk that the fair value or future cash flows of a financial asset will fluctuate because of changes in market interest rates.

Other price risk: this is the risk that the fair value or future cash flows of a financial asset will fluctuate because of changes in market prices (other than those arising from interest rate risk or currency risk), whether those changes are caused by factors specific to the individual financial instrument or its issuer, or factors affecting all similar financial instruments traded in the market.

The charitable company has exposure to these risks because of the investments it makes to implement its investment strategy. The Directors manage investment risks, including credit risk and market risk, within agreed risk limits which are set taking into account the charitable company's strategic investment objectives. These investment objectives and risk limits are implemented through the investment manager agreements in place with the charitable company's investment managers and monitored by the Directors by regular reviews of the investment portfolios.

Further information on the Directors' approach to risk management and the charitable company's exposure to credit and market risks are set out below.

Credit risk

The charitable company invests in pooled investment vehicles and is therefore directly exposed to credit risk in relation to the instruments it holds in the pooled investment vehicles and is indirectly exposed to credit risks arising on the financial instruments held by the pooled investment vehicles.

Analysis of direct credit risk

Direct credit risk arising from pooled investment vehicles is mitigated by the underlying assets of the pooled arrangements being ring-fenced from the pooled manager, the regulatory environments in which the pooled managers operate and diversification of investments amongst a number of pooled arrangements. The Directors carry out due diligence checks on the appointment of new pooled investment managers and on an ongoing basis monitor any changes to the regulatory and operating environment of the pooled manager.

Pooled investment arrangements used by the charitable company comprise authorised unit trusts.

Indirect credit risk arises in relation to underlying investments held in the bond pooled investment vehicles. This risk is mitigated by only investing in pooled funds which invest in at least investment grade credit rated securities.

Notes to the financial statements *(continued)*

9 Investments *(continued)*

Investment risks *(continued)*

Currency risk

The charitable company is subject to currency risk because some of the charitable company's investments are held in overseas markets, via the pooled investment vehicles.

Interest rate risk

The charitable company is subject to interest rate risk through investments comprising bonds.

Other price risk

Other price risk arises principally in relation to equities held in pooled vehicles. The charitable company manages this exposure to other price risk by constructing a diverse portfolio of investments across various markets.

10 Debtors

	2021 £	2020 £
Partnership Grant Debtors	114,728	-
Other debtors and prepayments	1,985,040	1,353,933
	2,099,768	1,353,933
	2,099,768	1,353,933

11 Creditors

	2021 £	2020 £
Amounts falling due within one year:		
Grants (note 5)	4,670,003	3,866,208
Accruals	47,926	56,162
Other creditors	172,612	80,577
Other taxes and social security costs	42,515	44,933
	4,933,056	4,047,880
	4,933,056	4,047,880
Amounts falling due after one year:		
Grants (note 5)	7,920,310	6,959,432
	7,920,310	6,959,432

Notes to the financial statements *(continued)*

12 Accumulated funds

	Unrestricted £	Designated £	Restricted £	Total £
2021				
At 31 December 2020	9,522,350	107,516	-	9,629,866
Income	10,766,184	-	52,465	10,818,649
Expenditure	(9,612,250)	(107,516)	(52,465)	(9,772,231)
Gains/losses	761,001	-	-	761,001
	<hr/>	<hr/>	<hr/>	<hr/>
At 31 December 2021	11,437,285	-	-	11,437,285
	<hr/>	<hr/>	<hr/>	<hr/>
	Unrestricted £	Designated £	Restricted £	Total £
2020				
At 30 September 2019	5,908,939	134,485	5,000	6,048,424
Income	9,487,732	-	249,837	9,737,569
Expenditure	(6,809,718)	-	-	(6,809,718)
Transfer	281,806	(26,969)	(254,837)	-
Gains/losses	653,591	-	-	653,591
	<hr/>	<hr/>	<hr/>	<hr/>
At 31 December 2020	9,522,350	107,516	-	9,629,866
	<hr/>	<hr/>	<hr/>	<hr/>

Notes to the financial statements (continued)

13 Restricted and designated funds

	UK Restricted £	Other Specified £	Prostate £	Restricted Funds £	Designated Prostate £
2021					
At 31 December 2020	-	-	-	-	107,516
Incoming resources	50,000	2,465	-	52,465	-
Outgoing resources	(50,000)	(2,465)	-	(52,465)	(107,516)
Transfer to/from restricted funds	-	-	-	-	-
At 31 December 2021	-	-	-	-	-
	Prof. K Ryan £	Dr S Leedham £	Prof K Hiom £	Other specified £	Designated Prostate £
2020					
At 31 December 2019	-	-	-	5,000	134,485
Incoming resources	1,000	237,000	6,837	-	-
Outgoing resources	-	-	-	-	-
Transfer to/from restricted funds	(1,000)	(237,000)	(6,837)	(5,000)	(26,969)
At 31 December 2020	-	-	-	-	107,516

The incoming resource of £50,000 represents a very generous donation focused on funding UK based research and was used for this purpose over the year. The Directors have designated a fund specifically for research into prostate cancer. Transfers in the prior year between designated and restricted funds were to cover costs in restricted funds as these were for the same purpose.

Notes to the financial statements *(continued)*

14 Analysis of net assets between funds

	Unrestricted £	Designated £	Restricted £	Total £
2021				
Fixed assets	48,586	-	-	48,586
Investments	15,825,908	-	-	15,825,908
Cash at bank and in hand	477,162	-	-	477,162
Other net current assets	3,005,939	-	-	3,005,939
Creditors of more than one year	(7,920,310)	-	-	(7,920,310)
	<u>11,437,285</u>	<u>-</u>	<u>-</u>	<u>11,437,285</u>
	Unrestricted £	Designated £	Restricted £	Total £
2020				
Fixed assets	79,883	-	-	79,883
Investments	14,648,791	107,516	-	14,756,307
Cash at bank and in hand	128,017	-	-	128,017
Other net current liabilities	1,625,091	-	-	1,625,091
Creditors of more than one year	(6,959,432)	-	-	(6,959,432)
	<u>9,522,350</u>	<u>107,516</u>	<u>-</u>	<u>9,629,866</u>

15 Reconciliation of net income to net cash from operating activities

	2021 £	2020 £
Net income	1,807,419	3,581,442
Income shown in investing activities	(371,121)	(371,049)
Net realised and unrealised losses/(gains) on investments	(761,001)	(653,591)
Depreciation	31,297	31,297
	<u>706,594</u>	<u>2,588,099</u>
Decrease/(Increase) in debtors	(745,835)	(88,566)
Increase/(Decrease) in creditors	1,846,054	(225,141)
	<u>1,806,813</u>	<u>2,274,392</u>

Notes to the financial statements *(continued)*

16	Commitments under operating leases	2021 £	2020 £
	Total future minimum lease payments under non-cancellable operating leases, due:		
	Not later than one year	97,129	97,129
	Later than one year and not later than five years	99,954	196,505
		<u>197,083</u>	<u>293,634</u>

17 Related parties

Professor Paul J Coffey has links with the University Medical Center, Utrecht, Professor Kevin J Hiom has links with the University of Dundee, and Professor Iain A McNeish has links with Imperial College London. Grants may be awarded to these Universities.

In November 2018, prior to his appointment as a Director, a grant of £190,955 was awarded to Professor Paul Coffey for a three-year research project that commenced in April 2019. At the year end, £80,881 remained payable on this grant award.

In October 2020, during his appointment as Director, a grant of £190,514 was awarded to Professor Kevin Hiom for a two-year project that commenced in May 2021. At the year end, £177,133 remained payable on this grant award.

The Directors are satisfied that the stringent and independent nature of the Scientific Advisory Committee's ensures that there is no conflict of interest.

During the year the charity received a donation of £500 from Morton Fraser, where one of our Trustees, Sue Hunter, is a partner.

18 Financial instruments

	2021 £	2020 £
Carrying amount of financial assets		
Financial assets measured at fair value	15,825,908	14,756,305
	<u>15,825,908</u>	<u>14,756,305</u>

Financial assets measured at fair value through the statement of financial activities are listed investments. Fair value of investments is market value at balance sheet date.

Notes to the financial statements *(continued)*

19 Grants awarded to institutions	2021 £*
University of South Australia (2 projects)	467,626
European Institute of Oncology (2 projects)	371,900
Universita degli Studi di Milano	204,800
University of Helsinki	222,228
VIB vzw	170,180
INSERM	186,040
The University of Manchester	204,192
Institut Curie, Paris (2 projects)	258,394
Fondazione Centro San Raffaele	206,893
Alexander Fleming Biomedical Sciences Research Centre	197,340
Karolinska Institute	225,000
CNR	171,500
University of Glasgow (co-funded with Pancreatic Cancer UK)	249,722
Imperial College London	217,531
University of Zurich	229,592
DKFZ (2 projects)	427,042
CBMSO-CSIC (co-funded with AECC)	229,455
QIMR Berghofer MRI (co-funded with Cancer Australia)	179,045
Queen Mary University of London	207,588
Foundation of Research and Technology	168,537
University of Padova	247,000
Institute of Oncology Research	180,000
	<hr/>
	5,221,605
	<hr/> <hr/>

* Grants shown at full award value including contribution of £329,112 from co-funders on three projects